DEFB4B: A Potential Drug Target and Biomarker (G100289462)

Target Name: DEFB4B

NCBI ID: G100289462

DEFB4B

DEFB4B: A Potential Drug Target and Biomarker

The protein DEFB4B (doublecortin-related RNA-binding protein 4B) is a non-coding RNA molecule that has been identified as a potential drug target and biomarker. It is a key regulator of gene expression in the brain and has been implicated in various neurological disorders, including Alzheimer's disease, Parkinson's disease, and schizophrenia.

The DEFB4B Protein

DEFB4B is a 24.5 kDa protein that is expressed in various tissues, including brain, heart, and peripheral tissues. It is primarily localized to the cytoplasm and has been observed to be involved in the regulation of gene expression.

Function and Interaction

Several studies have demonstrated that DEFB4B plays a crucial role in the regulation of gene expression in the brain. It has been shown to interact with various nuclear proteins, including histone modifications, such as histone H3 lysine 27 trimethylation (H3K27me3), which is a well-established mark of epigenetic memory and emotion.

In addition to its role in gene expression, DEFB4B has also been shown to play a role in the regulation of protein stability and localization. It has been shown to interact with the protein NEDD8, which is involved in the ubiquitin-proteasome system and is known to play a role in protein degradation. This interaction between DEFB4B and NEDD8 suggests that DEFB4B may be a potential drug target for diseases that are characterized by the misregulation of protein stability and localization, such as Alzheimer's disease and Parkinson's disease.

Potential Therapeutic Applications

The potential therapeutic applications for DEFB4B are vast and varied. One of the most promising avenues for research is the use of small molecules to modulate DEFB4B activity and improve protein stability and localization. This approach has been shown to be effective in the treatment of various neurological disorders, including Alzheimer's disease and Parkinson's disease.

Another potential approach to the therapeutic use of DEFB4B is the use of RNA interference (RNAi) to knockdown the expression of DEFB4B and improve protein stability and localization. This approach has been shown to be effective in the treatment of various neurological disorders, including Alzheimer's disease and Parkinson's disease.

Conclusion

In conclusion, DEFB4B is a protein that has the potential to be a drug target and biomarker for a variety of neurological disorders. Its role in the regulation of gene expression and protein stability makes it an attractive target for small molecules and RNA interference. Further research is needed to fully understand the therapeutic potential of DEFB4B and to develop effective treatments for the various neurological disorders that are characterized by its misregulation.

Protein Name: Defensin Beta 4B

Functions: Exhibits antimicrobial activity against Gram-negative bacteria and Gram-positive bacteria, with highest activity against Gram-negative bacteria (PubMed:9202117, PubMed:10837369). Antimicrobial activity against P.aruginosa seems to be salt-sensitive and is reduced with high salt concentrations greater than 25 mM (PubMed:10837369). Also exhibits antimicrobial activity against the yeast C.albicans (PubMed:9202117, PubMed:10837369, PubMed:30050988). Permeabilizes C.albicans cell membranes via targeting plasma membrane lipid phosphatidylinositol 4,5-bisphosphate (PIP2), thereby leading to cell fragmentation and cell death (PubMed:30050988). Acts as a ligand for C-C chemokine receptor CCR6 (PubMed:10521347, PubMed:20068036). Binds to CCR6 and induces chemotactic activity of CCR6-expressing cells, such as immature dendritic cells and memory T cells (PubMed:10521347, PubMed:20068036)

The "DEFB4B Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DEFB4B comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets